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Retroviruses that have the ability to infect germ line cells can become an integral and
inherited part of the host genome. About 8% of the human chromosomal DNA consists of
sequences derived from infections by retroviruses that presumably circulated 2–40 millions
of years ago, and some elements are actually much older. Post-insertional recombina-
tions, deletions, and mutations have rendered all known human endogenous retroviruses
(HERVs) non-infectious. However some, particularly the most recently acquired proviruses
of the HERV-K(HML-2) family, can expresses viral proteins and produce viral particles. In
this review we will first discuss the major aspects of the endogenization process and
peculiarities of the different HERV-K families. We will then focus on the genes and proteins
encoded by HERV-K(HML-2) as well as inactivation of these proviruses by postinsertional
mutations and their inhibition by antiretroviral factors. After describing the evolutionary
interplay between host and endogenous retrovirus we will delve deeper into the currently
limited understanding of HERV-K and its possible association with disease, particularly
tumorigenesis.
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INTRODUCTION
Human chromosomes contain numerous retroviral sequences that
form part of our genetic legacy. In total, human endogenous retro-
viruses (HERVs) sequences account for ∼8% of our genome.
With more than 500,000 elements, there are over 20-fold more
HERV sequences than there are human genes. These elements
typically have their origin in ancient infections of germ cells by
exogenous retroviruses that circulated ∼2–40 million years ago.
The human genome and the genomes of other vertebrate species
that contain endogenous retroviruses can therefore be regarded
as museums of ancient retroviruses. Phylogenetic studies have
allowed these elements to be sorted into distinct groups that are
usually termed “families.” Similar to artifacts in an archeological
museum, time has left its traces on these retroviral elements and
very often only “shards” of the once complete sequence remain.
All known proviruses in the human genome have suffered from
postinsertional mutations,deletions,and recombinations that ren-
der them non-infectious. Most often, only a single long terminal
repeat (LTR) remained. In contrast to humans, several other
species including mice and sheep carry infectious endogenous
retroviruses (1–3).
The most recently integrated and best preserved human
proviruses belong to a subgroup of the HERV-K elements dubbed
HERV-K(HML-2). The HERV-K group can be divided into 10
families (4). The designation “K” comes from their use of a lysine
tRNA to prime reverse transcription and human mouse mammary
tumor virus like-2 (HML-2) indicates their relationship to the
murine betaretrovirus mouse mammary tumor virus (MMTV).
More than 90 proviruses of the HML-2 family are exceptionally
well preserved and maintain open reading frames encoding func-
tional viral proteins (4). These proteins are expressed and non-
infectious particles are released in various cells, particularly in
tumors and cancer cell lines derived from teratocarcinomas and
melanomas (5–7). Moreover, two research groups have demon-
strated that consensus sequences of HERV-K(HML-2) elements
are able to produce infectious particles (8, 9). The infection and
replication of these particles is inhibited by a variety of restriction
factors including members of the APOBEC family, tetherin and
most likely other, yet to be identified antiviral factors that have
evolved over millions of years of coevolution between this virus
and its primate hosts.
HERV-K proviruses can be classified into two types. Only type
II proviruses express the accessory Rec protein that functionally
resembles the HIV Rev and HTLV Rex proteins (10, 11). Type I
proviruses have a 292-bp deletion that prevents expression of the
rec gene but can instead express an alternative protein called Np9.
Both Rec and Np9 are associated with malignancies. In addition to
the evidence for the protein-induced or promoted tumorigenesis
of somatic cells, HERV-K elements are also implicated in cancer
development at the DNA or RNA level. In this context, HERV-
K proviruses have been shown to be involved in recombination
events that in one setting left an LTR-promoter closely upstream
of exons 5–12 of the ETV1 gene that encodes a transcription factor
of the Ets family. Androgen-dependent expression of the protein
fragment driven by the viral LTR was correlated with an increase in
the invasiveness of prostate cancer (12). Promoters of other HERV
elements and retrotransposons have also been shown to stimulate
expression of nearby genes that promote malignancy (13). The
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number of known genes that are under definite transcriptional
control by HERVs and our understanding of the mechanisms
involved have dramatically increased in recent years (14).
In this regard it should be stressed that transcription of HERV-
K and other HERV elements is usually suppressed by epigenetic
factors such as DNA methylation and heterochromatin-silencing
by histone modifications (15). Nevertheless, it is estimated that
even in normal healthy cells, retroviral LTRs initiate 10 times as
many transcripts as regular promoters (16–19). The transcripts
induced include many RNAs that are complementary to regular
gene transcripts and can downregulate the expression of cellular
genes (17). During tumorigenesis (and also, presumably, in other
poorly understood situations) this epigenetic control can be par-
tially or selectively weakened and particular retroviral promoters
become able to vigorously activate the transcription of cellular
genes.
ENDOGENIZATION OF RETROVIRUSES WITH A FOCUS ON
HERV-K(HML-2)
The prerequisite for acquisition of a new endogenous retrovirus is
infection of a germ line cell that results in integration of the provi-
ral DNA into the cell’s chromosomal DNA. If this integration and
the possible replication of this founder virus do not prevent fertil-
ization, a fetus can form that carries the retroviral element in every
one of its somatic and germ line cells. From a genetic perspective,
the provirus becomes a regular host gene that is passed down the
generations, being inherited in a Mendelian fashion (20–22). Such
endogenization and transfer to offspring has been demonstrated
in the laboratory by infection of fertilized eggs with recombinant
avian leucosis virus (23). The viremia in the carriers can be attrib-
uted to replication of either the exogenous or the endogenous
form, which results in repeated infection of somatic cells. It can be
assumed that frequent recombination events occur at that stage by
copackaging of vRNAs,one from an inherited endogenous element
and one from an infecting exogenous virus with template switch-
ing by the reverse transcriptase (RT) occurring during subsequent
infection of a new host cell. To some degree, germ cells might also
be repeatedly infected, leading to further colonization of the germ
line and amplification of the number of viral elements belonging
to the same family. Other modes of amplification are also conceiv-
able and have been documented, including retrotransposition or
duplication of chromosomal regions that contain HERV elements
(24). However, in the case of HERV-K(HML-2) it appears that the
predominant mode of amplification within the human genome
has been reinfection by circulating infectious viruses over a period
of at least 30–40 million years (25). Colonization of the human
genome by this betaretrovirus did not occur at the same frequency
all the time: there were bursts of integration, during which the
replicative activity of the virus is assumed to have been high, inter-
spaced with longer periods of low integration (25). In recent years
the number of known human-specific HERV-K(HML-2) loci has
risen (4, 10, 26) and the lack of these loci in chimpanzees, our clos-
est primate relatives, proves that elements of this family continued
to reinfect our ancestors after their split from the chimpanzee
lineage about five to six million years ago. Although there is no
evidence for it being ongoing in humans, retroviral integration is
not something that only occurred in the distant past. In Australia
we are currently witnessing a fulminant endogenization process in
koala bears involving a retrovirus presumed to have been acquired
from a species of Asian mouse only a hundred or so years ago
(27–29).
The reproductive success of individuals carrying a germ line
provirus at a particular chromosomal locus determines the fre-
quency of this element in the population, i.e., it is subject to host
selection (Figure 1). Selective forces and fluctuations in the pop-
ulation size (first and foremost bottlenecks that simply by chance
increase the relative ratio of the carriers in the population) might
eventually result in fixation of the element. This means it is present
in all members of the population. It can be inferred that the likeli-
hood of an element reaching fixation correlates negatively with its
virulence if it compromises the reproductive success of the carrier.
It is therefore likely that neutral elements or elements that even
endow the carrier with a selective advantage are more likely to
reach fixation whereas those with a negative impact will not and
will eventually vanish. One piece of solid evidence in favor of this
hypothesis is the orientation of the endogenous elements found
in introns. Although integration has no preference with regard to
direction, the majority of HERVs have an orientation opposite to
that of the gene they have integrated next to, usually rendering the
splice sites and other regulatory elements inactive. Elements that
occurred in the same orientation as the gene vanished with higher
frequency because they can modify expression of the encoded cel-
lular protein to the detriment of the host. In contrast, there are
only very few elements that are obviously under strong positive
selective pressure, none of which belong to the HERV-K(HML-2)
family (30).
HERV-K FAMILIES
To date, there is little known about members of the HERV-
K superfamily other than HERV-K(HML-2). All HML families
belong to the class II/betaretrovirus group, which also contain
the endogenous and exogenous MMTV, Mason–Pfizer monkey
virus (MPMV), and Jaagsiekte sheep retrovirus (JSRV) (31). Ele-
ments such as HML-4 and HML-6, which are related to but clearly
distinct from the HERV-K(HML-2) prototype virus HERV-K10
(32), were identified more than 20 years ago by extensive lab
work using low-stringency Southern blot analyses with MMTV-
derived gag/pol probes (33). These data were later complemented
by PCR and the sequences were grouped into the HERV-K fam-
ilies HML-1 to HML-6, based on the sequences of a conserved
RT region (34). These results were subsequently compiled to yield
our current understanding that there are up to 10 HERV-K(HML)
families in addition to a related family HERV-K(14C) present in
the human genome (35). As the complete human genome has
now been sequenced, identification of HERV elements can now be
performed with relative ease by database analyses. Searching for
sequences derived from the cloned HERV-K (HML-1 to HML-10)
elements reveals a probable total of about 550 HERV-K proviruses
and 6400 solitary LTRs in the human genome (36), ranging from
150 HML-3 proviral elements to 5 HML-4 proviruses, for exam-
ple (24, 37). Not all HML families are described in detail using
in silico generated consensus sequences or by analysis of individ-
ual elements, a summary of the features of HERV-K families is
given in Table 1, although these numbers may need to be revised
as was recently done for HML-2 solo LTRs, being adjusted from
∼2500 to 944 (4, 38).
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FIGURE 1 | Hypothetical model for an increase in allelic frequency and eventual loss or fixation of an endogenized element integrated at a particular
chromosomal locus.
Table 1 | Class II/HERV-K (human MMTV-like) families.
Name Alternative names Estimated time of
integration (mya)
Estimated copy number
in genome
Reference
Proviruses Solo LTRs*
HML-1 NMWV6, HERV-K14I ∼39 68 350 Franklin et al. (33), Medstrand and Blomberg (34), Flockerzi
et al. (41)
HML-2 NMWV1, HDTV ∼35–2 91 944 Subramanian et al. (4), Bannert and Kurth (24), Ono (42)
HML-3 NMWV5, HERV-K9I ∼36 140 700 Franklin et al. (33), Medstrand and Blomberg (34), Mayer
and Meese (43)
HML-4 HERVK13I, HERV-K-T47D ∼55–35 5 800 Medstrand and Blomberg (34), Seifarth et al. (37)
HML-5 NMWV2, HERV-K22I ∼55 139 600 Franklin et al. (33), Lavie et al. (40)
HML-6 NMWV4, HERV-K3I ∼30 30–40 50 Franklin et al. (33), Medstrand et al. (44), Yin et al. (45)
HML-7 NMWV7, HERV-K11D1 n.d. 20 140 Franklin et al. (33), Andersson et al. (35)
HML-8 NMWV3, HERV-K11I n.d. 60 600 Franklin et al. (33), Andersson et al. (35)
HML-9 NMWV9 n.d. 10 40 Franklin et al. (33), Andersson et al. (35)
HML-10 HERV-K(C4) ∼30 10–50 100 Jern et al. (31), Tassabehji et al. (46)
*Most copy numbers of solo LTRs given in Ref (24); mya, million years ago; n.d., not determined.
The oldest group within the HERV-K superfamily appears to
be the HERV-K(HML-5) family. Based on the traditional crite-
rion for naming the HERV elements, HML-5 proviruses could
constitute the HERV-M family, as the primer binding site of
the consensus sequence is identical to the 3′ end of methio-
nine tRNA. These elements are not found in prosimians, and
are the only HERV-K proviruses in both Old World and New
World monkeys, suggesting that the integration event must have
taken place 35–55 million years ago. An even more precise esti-
mate for the time of integration can be made by examining
the LTRs. At that point in time, both LTRs in the viral genome
would have been identical, but in the host genome they would
accumulate random mutations at a rate of 2.3–5× 10−9 sub-
stitutions per site per year (39), i.e., one difference between
the two LTRs would be generated every 200,000–450,000 years.
Although this kind of estimation has several limitations, includ-
ing the fact that there were certainly periods of varying muta-
tional rates, the integration of HML-5, based on LTR–LTR diver-
gence, is estimated to have occurred ∼55 million years ago. It
is interesting to speculate whether the age of HML-5 makes
it the ancestor of other HERV-K families. However, sequence
comparisons show that HML-5 does not lie at the root of the
HERV-K phylogenetic tree, suggesting that this is probably not the
case (40).
Remarkably, within the HML-1 family seven proviruses were
found in which gag, pro, and pol sequences have been replaced by
similar regions from HERV-W, resulting in hybrid structures (41).
Such recombination events can occur by template switching by
RT or at the DNA level. However, the differing flanking cellular
sequences indicate that at some point the initial hybrid provirus
was able to form progeny proviruses in the genome through a
transcript.
HERV GENES, TRANSCRIPTS, PROTEINS, AND STRUCTURE
To varying degrees, endogenous retroviruses are phylogeneti-
cally similar to exogenous retroviruses and it is therefore com-
mon to categorize them into three different classes. While class
I HERV elements (e.g., HERV-W, HERV-FRD) have similarities
to exogenous gammaretroviruses (e.g., MLV, GaLV) and class III
HERV (e.g., HERV-L) are distantly related to lenti- or spuma-
like retroviruses (e.g., HFV), the structure of a HERV-K(HML-1
to HML-10) element resembles a typical betaretrovirus (31). As
HERV-K(HML-2) elements, in addition to the four major ORFs
for gag, pro, pol, and env, also encode an accessory gene similar to
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those of delta-, lenti-, and spumaviruses they were defined as com-
plex endogenous retroviruses. HML-2 type II proviruses encode
an HIV-1 Rev- or HTLV-1 Rex-like protein termed Rec and only
26% of HML-2 elements are classified as type I expressing the pro-
tein Np9 (4, 47, 48). The genomic organization of these proviruses
and their resulting RNA transcripts are shown in Figure 2.
The full-length HML-2 mRNA encodes the structural proteins
of Gag, termed matrix (MA, p15), capsid (CA, p27), nucleocapsid
(NC, p10) plus three smaller peptides as well as the putative phos-
phoprotein (pp15) (49). Due to two slippery sites and the resulting
−1 bp ribosomal frameshifts, the Gag-Pro and Gag-Pro-Pol pre-
cursor proteins are produced and processed into the protease (Pro)
enzyme and into polymerase (Pol) that exhibits RT and integrase
(IN) activity. The single spliced mRNA for Env encodes the typi-
cal retroviral Env protein consisting of a signal peptide, a surface
unit (SU; ∼44 kDa), and a transmembrane unit (TM; ∼26k Da).
A functional Env protein has only been described for the HERV-
K108 provirus (50), although the infectivity of another HERV-
K(HML-2) element (K113) could be restored by back mutation of
putative post-insertional amino acid changes (51). In addition to
another two mRNAs coding for the accessory proteins Rec or Np9
that will be addressed in detail later, a 1.5-kb transcript termed hel
has been found in human teratocarcinoma cell lines (48) although,
as this mRNA does not encode a protein, its function requires
clarification.
Some exogenous and endogenous retroviruses code for a
dUTPase in addition to the enzymes essential for the retroviral
life cycle such as RT, RNase H, Pro, and IN. dUTPase catalyzes
the degradation of dUTP in order to prevent the toxic misincor-
poration of uracil into the newly forming proviral DNA. Both
betaretroviruses and non-primate lentiviruses [i.e., Maedi-Visna
virus (MVV) and equine infectious anemia virus (EIAV)] feature a
dUTPase, albeit located in different regions of the genome (31, 52).
The dUTPase in betaretroviruses is found within the N-terminal
region of pro whereas in non-primate lentiviruses it is in pol.
POSTINTEGRATIONAL MUTATIONS AND REPLICATION
POTENTIAL OF HERV-K
It can be assumed that unless antiretroviral cellular factors of
the APOBEC-superfamily were deaminating their genomes during
reverse transcription, the majority of HERV-K(HML-2) elements
were replication competent for some period of time after integra-
tion into the germ line cell genome. HERV-K(HML-2) is particu-
larly susceptible to APOBEC 3F and APOBEC 3G deamination as
shown in infectivity assays using infectious viruses produced with
HERV-K(HML-2) consensus sequences (9, 53). Moreover, 2 of 16
(53) most recently integrated elements known are substantially
mutated by APOBEC deaminases, indicating that these antiviral
factors were already active several millions of years ago. How long
elements that escape restriction by deaminases are usually able to
produce infectious viruses is an open question. It is known that
some endogenous retroviruses of pigs, sheep, and other animals
have resided in their host’s genomes for tens or even hundreds of
thousands of years and yet retain open reading frames and remain
both replication competent and infectious (21). Some replica-
tion competent porcine endogenous retroviruses in Old World
pig species are presumably even older (3).
It is known that during their residency in the host cell genome,
endogenous elements acquire postinsertional mutations and dele-
tions that can inactivate the provirus. Recombination events fre-
quently take place that delete most of the proviral sequence,
leaving just an LTR (solo LTR). With HERV-K, solo LTRs out-
number elements still framed by both LTRs by a factor of at least
10. In contrast to these single LTR remnants, HERV-K(HML-2)
proviruses also exist that possess open reading frames for all viral
genes. Such elements include variants (haplotypes) of HERV-K113
and HERV-K108 that are thought to be two of the most recently
acquired elements (4, 26). However, post-insertional mutations
other than those that generate premature stop codons have since
rendered these viruses replication incompetent (36, 54): infection
could not be achieved using supernatants from germ line cells that
FIGURE 2 | Proviral organization of HERV-K(HML-2) and RNA transcripts. The black bar represents a 292-bp deletion that results in the Np9 gene product for
type I proviruses instead of the Rec (an HIV-1 Rev homolog) characteristic of the type II proviruses. Hel is a poorly described RNA without protein coding
function.
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release HERV-K(HML-2) particles. Indeed, none of the currently
known HERV-K(HML-2) elements appear to have the capacity
to produce infectious particles. It is not known when the most
recent HERV-K(HML-2) endogenization occurred and when the
last provirus lost its ability to replicate. In fact, although unlikely,
the existence of an infectious HERV-K(HML-2) provirus with low
prevalence in the current human population cannot be completely
ruled out.
Even if no functional HERV-K(HML-2) element is currently
extant in humans, an infectious virus might nevertheless be reborn
as a chimera of partially inactivated parental elements. That
infectious retroviruses can form by recombination between the
RNA genomes of two inactivated parental elements is well doc-
umented, with the two most recent occasions involving murine
gammaretroviruses, including the notorious XMRV (55, 56). Sim-
ilar events could also result in the reconstitution of a replication
competent HERV-K(HML-2) element. Indeed, Heidmann and
Co-workers have demonstrated in vitro the reconstitution of an
infectious HERV-K(HML-2) element through recombination of
three HERV-K(HML-2) elements (8). Compared to exogenous
retroviruses, the infectivity of such reconstituted particles is rather
poor and productive replication in cell culture has yet to be demon-
strated. It is therefore likely that despite the demonstration of
in vitro infection and integration, restriction factors including
APOBEC have evolved to prevent productive replication in cell
culture and in vivo. However, HERV-K(HML-2) does not appear to
be a target of human Trim5alpha, an antiretroviral factor attacking
the capsids of infecting retroviruses (9).
ROLE OF HERV-K IN HUMAN EVOLUTION AND PHYSIOLOGY
In addition to the examples described in more detail below, trans-
posable elements, including HERVs, generally drive alterations of
the human genome by providing RT, an enzyme that can facilitate
gene duplication for example, and by the addition or modu-
lation of promoter activities. Even before the human genome
was sequenced, it was suggested that constant updating of the
transcriptional pattern through evolution of cis-acting elements
might contribute more to species diversity than do changes in
coding regions themselves (57). The simple insertion of an LTR
can replace the original promoter, alter tissue specificity, or add
enhancer activity (16). Of course, the LTRs acting as mobile
genomic elements originate from full-length, inserted retroviruses.
Hypothetically, there are three possible outcomes of retrovi-
ral host genome invasion, i.e., genetic modification by the foreign
DNA and/or the impact at the specific point of integration can
be beneficial, harmful, or neutral for the individual. Retroviral
integrations that severely harm the host genome, for example by
interfering with the regulation of gene expression through pro-
moter activity or direct destruction of coding regions, cannot play
a significant role in human evolution because affected individuals
are subject to negative selection and are removed from the gene
pool. On the other hand, positive effects of altered gene expression
through retroviral integration are well known. For example, the
amylase gene is expressed in the pancreas of all mammalian
species. However, in primates, rodents, and lagomorphs (rabbits,
hares, and pikas), amylase is also expressed in the salivary gland as
a result of gene duplication and insertion of a retroviral sequence
(58), an event that probably helped these species to include starch
in their diets.
Perhaps the most striking example of mammalian exploita-
tion of retroviral sequences is the co-option of an endogenous
retrovirus envelope gene to form the syncytiotrophoblast during
pregnancy. The main function of the retroviral envelope protein
is to mediate fusion of virus and target cell membranes during
infection, making it an ideal “tool” to facilitate cell–cell fusion.
The HERV-W (59) and HERV-FRD (60) glycoproteins, expressed
exclusively in the placenta, are therefore termed syncytin-1 and -2,
respectively. Furthermore, the envelope proteins are involved in
retrovirus-induced immunosuppression (61) and as the placenta,
as far as the mother’s immune system is concerned, is an allogeneic
organ, local immunological tolerance is necessary to prevent rejec-
tion of the fetus. This capacity for immunosuppression, shown for
syncytin-2, but so far not for syncytin-1 (59), may therefore be
another reason that the endogenous retroviral env is expressed in
the human placenta.
Further evidence for the deliberate co-option of retroviral genes
during host evolution includes the presence of syncytin-A and -B
genes in the murine genome, genes that have the same functions as
their human counterparts but are clearly distinct at the sequence
level (62). With mice it is possible to directly study the impact
of these genes and “knocking out” syncytin-A results in disrupted
placental architecture and the in utero death of embryos (63).
The later discovery of syncytin genes in other mammals demon-
strates that the exploitation of retroviral env genes has occurred
independently and on multiple occasions throughout mammalian
evolution. It is exciting to speculate that the first retroviral env
integration in an oviparous species marked the beginning of the
change from egg-laying prototherians to placental mammals (64).
A more direct advantage for the host of endogenization may be
protection from infection by related exogenous pathogenic retro-
viruses. One well-studied example of this is sheep that carry an
endogenous form of JSRV and are therefore protected against
infection by exogenous JSRV (65) through receptor interference by
the endogenous retroviral envelope. Furthermore, the Gag protein
of defective transdominant endogenous JSRV interferes at a late
stage of replication with the exogenous form of the protein (66),
a phenomenon also described in mice in which expression of an
endogenous retroviral Gag protein with homology to the HERV-L
family blocks various strains of exogenous MLV (67). To date, no
comparable function for HERV-derived proteins is known, but it
is very plausible that the open reading frames retained for some
HERVs serve a similar purpose.
EXPRESSION AND REACTIVATION OF HERV-K LOCI IN
HEALTH AND DISEASE
Although HERV-K(HML-2) gene expression is largely repressed in
most cells by epigenetic silencing, low-level expression occurs in
some tissues. Various groups have found that between 7 and 30%
of all HERV sequences in the genome are transcriptionally active
(18, 68, 69). In particular, the testes and placenta appear to be priv-
ileged tissues for HERV expression (69). There is an ongoing and
active debate about HERV expression in healthy tissues, with some
authors assuming a possible advantage for cells that express HERV-
K proteins (70). Expression of the HERV-K envelope protein TM
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subunit in placental cytotrophoblast cells suggests its potential
involvement in placentogenesis and pregnancy (71), as discussed
above for syncytin-1 and -2. Moreover, Wang-Johanning and Col-
leagues have detected low-level expression of HERV-K env mRNAs
and proteins in healthy ovarian tissues (72).
Andersson and Colleagues made the very interesting discovery
of HERV-K rec transcripts in the placenta and in various other nor-
mal human fetal tissues, suggesting that this small RNA transport
molecule may play a role in the development and differentiation
of human tissues (73).
Although HERV-K is expressed at only very low levels (if at
all) in healthy tissues, activation of transcription, and protein
production is associated with diseases such as cancer and autoim-
mune disorders. Indeed, the possible role played by upregulation
of HERV-K expression in autoimmune diseases such as multiple
sclerosis (MS) and rheumatoid arthritis (RA) is being investigated.
Rheumatoid arthritis is a chronic, systemic inflammatory disor-
der that especially affects synovial joints. Serological and molecular
assays show a significant increase of HERV-K gag expression in RA
patients compared to inflammatory and healthy control groups
(74). Furthermore, exogenous viral protein expression and proin-
flammatory cytokines enhance HERV-K gag transcription. Finally,
anti-HERV-K antibodies with possible cross-reactivity to host
proteins could cause autoimmune responses through molecular
mimicry (74).
Multiple sclerosis is more controversial, and although the etiol-
ogy of this disease remains unknown it is likely that the trigger for
MS is multifactorial. One interesting hypotheses involves a neu-
rotropic infectious agent, possibly a virus, and HERV-K(HML-2)
is one candidate in this context (75). Indeed, Tai and Colleagues
found HERV-K18 expressing a superantigen in its env gene to
be a risk factor for MS (76) and although this observation was
made in a very small cohort, it is exciting because expression of
HERV-K18 superantigen is also elevated in juvenile RA (77). There
is also some evidence that, depending on the population, the LTR
sequences of HERVs such as HRES-1 show polymorphisms within
MS patient haplotypes while those from non-MS patients are iden-
tical without geographic restrictions (78). However, Moyes and
Colleagues have published data showing that HERV-K113 and
HERV-K115 are not significantly increased in patients with MS
compared to the combined parent group (79, 80) and their results
do not therefore support an association between these particular
endogenous retroviruses and MS (79, 81). Finally, various groups
have reported an association between HERV-K18 polymorphisms
and type 1 diabetes (82, 83). In summary, a correlation between
HERV-K expression and autoimmune disease is neither refuted
nor proven. A definite conclusion will need to be based on a great
deal more data.
In contrast to the situation with autoimmune diseases, the pic-
ture concerning HERV-K expression in malignant diseases is much
clearer. As already mentioned, the expression of HERV-K(HML-2)
in malignant tissues such as germ cell tumors (GCTs), melanomas,
or ovarian cancers is considerably higher than in healthy tissues (5,
6, 70, 72, 84–86). A number of malignant diseases suggested to be
associated with HERV-K expression are listed in Table 2. HERV-K
expression was first observed in GCTs (87–89) and is often associ-
ated with the release of HERV-K(HML-2) particles. The frequent
induction of an immune response to HERV-K(HML-2) Gag and
Env proteins (90, 91) is well documented in patients with GCT
disease. The presence of antibodies specific for HERV-K(HML-
2) proteins correlates strongly with the clinical manifestation of
GCTs and may therefore be used as a diagnostic and prognos-
tic marker for these types of cancer (92). Interestingly, HERV-K
expression in teratocarcinoma cell lines can be further enhanced by
androgens (93), although, it is still unknown whether the andro-
gen receptor (AR) binds directly to HERV-K LTRs or acts via other
host proteins. Direct binding of other cellular proteins and tran-
scription factors to the HERV-K(HML-2) LTR have already been
demonstrated (94, 95).
Beside teratocarcinomas HERV-K proteins are expressed in
90% of epithelial ovarian tumors but at only very low levels,
if at all, in healthy tissues or benign tumors (72). Activation of
HERV-K expression in ovarian cancer might occur in response to
stimulating transcriptional factors that are expressed in malignant
ovarian cells (96). Such mechanisms, which lead to hypomethyla-
tion and subsequent enhancement of HERV-K transcription, have
been already described for HERV-H and HERV-W elements in the
ovaries (97–100) and for HERV-K in urothelial cancer and GCTs
(101, 102).
Expression of HERV-K in melanomas has been the subject
of intense study by many groups (6, 86). Both mRNA and Gag,
Env, Rec, Np9, and RT proteins have been detected in specimens
from primary and metastatic melanoma biopsies and melanoma
cell lines but not in melanocytes or normal lymph nodes (6, 86).
Muster and colleagues even observed retrovirus-like particles con-
sisting of mature forms of Gag and Env and having RT activity
(86). About 85% of malignant melanocytes express HERV-K MEL
that is produced by a pseudo-gene incorporated into the HERV-
K env gene and which has already been defined as a marker for
melanoma risk (103–105). In accordance with the high levels of
HERV-K expression, antibodies specific for Env and Gag were
detectable in the sera of 16–22% of melanoma patients but not
in those of healthy controls (6, 106). Hahn et al. showed in 2008
that the immune response of melanoma patients against HERV-
K gene products correlates negatively with their survival (106).
In line with existing knowledge about melanoma development,
HERV-K expression can be triggered by UV radiation and may
therefore be able to accelerate carcinogenesis (107, 108).
In addition to teratocarcinomas, ovary tumors, and
melanomas, elevated levels of HERV-K(HML-2) env RNA were
also detected in breast cancer tissues and gag RNA was found in
the peripheral blood cells of leukemia patients as well as in breast
and prostate cancers (109–112). The possible influence of steroid
hormones on HERV-K activity in both breast cancer and prostate
cancer is being discussed, with various groups reporting a stim-
ulating effect of estroprogestin on HERV-K env transcription in
breast cancer cells (110, 112, 113).
It was reported in early 2006 that, in contrast to patients
undergoing successful HAART or to seronegative controls, HERV-
K(HML-2) RNA can be found in the plasma of HIV-1 infected
individuals whose antiretroviral therapy fails to control virus repli-
cation (114, 115). Subsequently, it was even possible to observe
virus-like particles by electron microscopy and by immunostain-
ing using HERV-K Env and Gag specific antibodies (116). A
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Table 2 | List of malignant diseases that are associated with HERV-K(HML-2) activity.
Tissue Cancer HERV-K(HML-2) activity Reference
Skin Melanoma Retroviral particles Buscher et al. (6), Muster et al. (86), Hirschl
et al. (124)Enhanced transcription
RT activity
Expression of Env, Rec, Np9
Testes Germ cell tumors,
gonadoblastoma, seminoma
Anti-Gag/Env-Ab Boller et al. (87), Kleiman et al. (92), Boller et
al. (125)Expression of Rec, Np9
Ovary Ovarian clear cell carcinoma;
ovarian epithelial tumors
Expression of Gag and Env Gotzinger et al. (15), Wang-Johanning et al.
(72), Iramaneerat et al. (126)
Breast Breast cancer Free viral RNA Wang-Johanning et al. (112),
Contreras-Galindo et al. (127),
Wang-Johanning et al. (128)
RT activity
Virus particles
Specific CTLs
Prostate Prostate cancer Enhanced Gag-production due to fusion to
androgen-dependent ETV1 and ETS genes
Tomlins et al. (12), Lamprecht et al. (13),
Ishida et al. (111)
Blood Lymphoma Free RNA Contreras-Galindo et al. (127)
RT activity
Virus-like particles
possible mechanism for preferential HERV-K expression in HIV-1
infected cells could be the interaction between HIV-1 Rev and the
Rec response region in HERV-K(HML-2) RNA (11, 117) as well as
the recently demonstrated susceptibility of the HERV-K (HML-2)
transcriptional promoter to HIV-1 Tat (118).
The putative association between HERV-K(HML-2) expression
and HIV-1 infection is strengthened by the detection of HERV-
K specific cytotoxic T-cells in HIV-1 infected individuals (119).
Interestingly, such HERV-specific T-cells are not found in HTLV-1
infected individuals (120), although this latter study cannot com-
pletely rule out an involvement of HERV activation in HTLV-1
pathogenesis. HERV-K specific CD8+ T-cells that can recognize
and kill cells presenting the cognate peptides as a result of HIV-
induced expression of HERV proteins (119) may play an important
part in the natural immune response to HIV (121). In contrast to
HIV specific CD8+T-cells that are compromised in their ability to
cope with the profound diversity of HIV-1 and subsequent appear-
ance of escape mutants, the HERV proteins remain unchanged
throughout the course of infection. Having an unchanging target
allows HERV-specific T-cell clones from HIV-1 infected individ-
uals to kill, in vitro at least, human CD4+ cells infected with
viruses as diverse as HIV-1, HIV-2, and SIV (122). The stimulation
of HERV-specific T-cells may therefore offer a new approach to
inducing a broadly specific anti-HIV immune response. Of course,
this approach is currently hampered by our limited understanding
of HERV antigen expression in different individuals, tissues, and
diseases (123).
IMPLICATIONS FOR CANCER DEVELOPMENT
Whether HERV-K expression is an initiator of cancerous processes
or is simply a consequence of malignant degeneration remains a
topic of discussion. Many groups have found evidence for the
involvement of HERV-K in tumor processes and various hypothe-
ses concerning its potential contribution to oncogenesis have been
postulated. These possible mechanisms include the misregulation
of oncogenes, protooncogenes, or growth factors by HERV-K LTRs
or HERV loci. Several examples of transcriptionally active HERV
loci that influence neighboring genes by providing alternative
promotors are known (13, 129). Hypomethylation often affects
HERV-derived solo LTRs that function as alternate promoters,
for example the HERV-derived LTR is hypomethylated in B cell-
derived Hodgkin’s lymphoma and is responsible for deregulated
expression of the colony-stimulating factor 1 receptor (CSF1R), a
protooncogene (13). Another possible mechanism for HERV loci
to affect cellular gene transcripts is by the provision of alternative
splice and polyadenylation sites [reviewed in Ref. (16)].
A second mechanism of tumor induction/promotion by
HERV-K is the inactivation of tumor suppressor genes by de novo
insertion or translocation of retroelements within the genome
(70, 130). Recombination involving HERV-K sequences might
also lead to chromosomal instability and large-scale chromoso-
mal anomalies such as those typically observed in aberrant cells
(131, 132).
A third mechanism is the expression of HERV proteins such as
Rec and Np9 that function as oncogenes or of proteins that induce
cell–cell fusion such as Env. It is possible that cell fusions initi-
ated by Env contribute to tumor progression or might even play
an important role in metastasis (133). Furthermore, Env is con-
sidered to have immunosuppressive properties and may therefore
play a role in tumor escape processes (133–135). HERV-K may
trigger the pathological processes that lead to melanoma develop-
ment and contribute to the cellular modifications implicated in
melanoma maintenance and progression (96, 136). UV radiation,
hormone action, or mutating viruses lead to enhanced expression
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of HERV-K proteins such as Env or the HERV-K MEL-antigen
that is particularly expressed in melanomas (96, 107, 137). The
HERV-K Env protein is a molecular mimic of the oxygen respon-
sive element binding protein (OREBP), a human nuclear factor
that controls the expression of glutathione peroxidase, resulting in
reduced production of the enzyme (137). This further increases
the toxicity of free radicals that are no longer under proper control
and enhances the risk of cancer.
POTENTIAL ONCOGENES: Rec AND Np9
In recent years evidence has accumulated to indicate a role for the
accessory HERV-K(HML-2) protein Rec and for Np9 in tumor
development. Rec is a 14.5-kDa protein, translated from a dou-
bly spliced transcript (Figure 2), that mediates the transport of
unspliced or partially spliced HERV-K(HML-2) mRNAs from the
nucleus into the cytoplasm (11). In 2005, Galli and Co-workers
demonstrated that transgenic mice expressing Rec show distur-
bances in germ cell development and that some animals develop
lesions similar to the predecessor lesions of classical semino-
mas in humans (138). This indicates that HERV-K(HML-2) Rec
expression might play a direct role in cell transformation, creating
a pre-cancerous state, although the molecular mechanisms and
pathways involved remain elusive.
The cellular interaction partners of Rec are also poorly defined,
although some have recently been identified. Rec interacts with the
promyelocytic leukemia zinc-finger protein (PLZF) that is essen-
tial for the self-renewal of spermatogonial stem cells in mice and
which may also be involved in certain human leukemias (139–
142). Transient co-expression of Rec with PLZF interferes with
its function as a negative regulator of the c-myc protooncogene
and cells stably transfected with PLZF and Rec show increased
cell proliferation (142). Recently, Kaufmann et al. reported that
Rec forms trimeric complexes with the testicular zinc-finger pro-
tein (TZFP) and the AR (143). These data support the findings of
other groups, including our own. Rec interacts directly with the
human small glutamine-rich tetratricopeptide repeat-containing
protein (hSGT), a co-chaperone and negative regulator of the AR
(93, 144). Binding of Rec to the co-chaperone abrogates its abil-
ity to bind to the AR and to maintain it in an inactive state (93),
which in turn leads to enhanced levels of AR activity. It is interest-
ing that HERV-K transcription (and subsequently Rec expression)
can be stimulated by hormones, including androgens, and various
steroid hormone-binding sites are predicted to be located within
the HERV-K LTR (89, 93, 95, 113).
In contrast to Rec, Np9 has no known physiological function in
HERV-K replication. This 9 kDa protein is produced by viruses
lacking a 292-bp sequence within the pol-env boundary. Np9,
whose first 15 amino acids are identical to Env and Rec, is expressed
exclusively in various tumor tissues such as breast cancer, GCTs,
ovary cancer, and leukemia (47, 145). It is therefore important to
identify host proteins potentially interacting with Np9.
Np9, like Rec, binds to the PLZF protein, albeit in a different
region. Also like Rec, Np9 is able to abrogate the regulator of the c-
myc protooncogene, leading to increased c-myc transcription that
in turn leads to enhanced cell growth and reduced apoptosis (142).
Np9 has also been shown to interact with the ligand of Numb
protein X (LNX), a RING-type E3 ubiquitin ligase that ubiqui-
tylates Numb and marks it for degradation by 26S proteasomes
(146). Numb is an antagonist of the transcription factor Notch
and both proteins regulate the pro-proliferative Ras signaling
cascade. Misregulation of this system has been linked to breast
cancer, leukemias, and GCTs (147–151). Furthermore, Chen and
Co-workers recently reported that Np9 is a potent viral oncogene
in human leukemia (145). This small protein promotes growth of
myeloid and lymphoblastic leukemic cells by activation of ERK,
AKT, and Notch1 pathways and by upregulation of β-catenin. The
latter is essential for survival of leukemia stem/progenitor cells.
CONCLUDING REMARKS AND OUTLOOK
The examples of HERV activity described in this review make it
clear that these elements are not simply pieces of “junk DNA” that
litter the genome because a mechanism to completely remove an
integrated retrovirus from the germ line does not exist. Despite
having been discovered in the late 1960s, it appears that many of
the intricate evolutionary and physiological roles in health and dis-
ease played by the retroviral part of our own genome still remain
to be revealed. In addition, many questions concerning the endo-
genization process, the interplay of coexisting endogenous and
exogenous forms, population dynamics, and the fixation of ERVs
remain open. The regulation of human genes by HERV-K(HML-2)
and other HERV families and the silencing and restriction mech-
anisms by which the host controls their activities are currently of
particular interest.
From a virological point of view, the reconstitution of con-
sensus sequences and expression of original HERV-K(HML-2)
proteins have greatly facilitated studies into the functional role
of viral proteins in the replication cycle and in cellular processes.
This, as well as the increasing availability of whole genome
sequences, significantly enriches the exciting and novel field of
“paleoretrovirology.”
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